Redirecting to https://www.jnj.com/media-center/press-releases/darzalex-faspro-based-quadruplet-regimen-approved-in-the-u-s-for-newly-diagnosed-patients-with-multiple-myeloma-who-are-transplant-ineligible...

Click here if your browser doesn't automatically take you to this page.